Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Merck ​and Daiichi ‌Sankyo have ​voluntarily ​withdrawn their ⁠US ​application ​seeking accelerated approval ​for ​their experimental lung ‌cancer ⁠therapy, the ​drugmakers ​said ⁠on Friday.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。